Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics
This article was originally published in The Pink Sheet Daily
Executive Summary
The $60 mil. deal gives Wyeth rights to three different dosage forms of methylnaltrexone for a range of opioid-induced conditions.
You may also be interested in...
First Roche, Then Bristol: Who’s Next?
This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.
First Roche, Then Bristol: Who’s Next?
This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.
Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation
Companies will meet with FDA in May to discuss new study for an oral formulation, Wyeth tells “The Pink Sheet” DAILY.